Novartis pays $2B for stealth allergy biotech Excellergy, five years after founding
Mar 27, 2026
Key Points
- Novartis acquires stealth biotech Excellergy for $2 billion to secure EXL-111, a next-generation IgE therapy positioned to replace its $1.7 billion blockbuster Xolair before patent expiration.
- CEO Todd Sbodinik executes the specialist biotech playbook for the third time in two years, selling Excellergy within a year of joining after prior exits at $2.4 billion and $1.2 billion.
- Pharma companies deploy AI agents to accelerate drug development through incremental gains: parsing FDA filings faster, managing compliance work, and submitting applications weeks earlier than traditional methods.
Summary
Novartis acquired Excellergy, a five-year-old stealth biotech, for $2 billion this week. Founded on academic research from Stanford and the University of Bern, Excellergy developed EXL-111, a next-generation IgE-targeting therapy designed to work faster and last longer than existing allergy treatments. The company dosed its first Phase 1 patients in February before Novartis closed the deal weeks later.
Novartis generates $1.7 billion annually from Xolair, the current blockbuster in the allergy drug category, but key patents expire soon. A next-generation IgE asset is strategically valuable as a bolt-on to extend the immunology business line. The acquisition price splits between upfront payment and development and commercial milestones, a structure that hedges risk. If Phase 2 trials falter, some payment gets clawed back.
CEO Todd Sbodinik joined Excellergy in 2025 and sold it within a year. This follows a documented pattern: he sold Zeltic to Allergan for $2.4 billion and Dermavant for $1.2 billion in 2024. Markets respond calmly to his moves because the playbook is proven and repeatable.
Pharmaceutical companies are quietly leading AI adoption in ways that differ sharply from software narratives. Pharma uses AI agents not to cure disease at scale but to handle mechanical compliance work. These systems parse 10,000-page FDA filings, check supply chain documentation, and manage Word document variations for multi-indication submissions. The gains are incremental: submit a week earlier, investigate more literature faster, summarize IP faster. These gains compound into measurable acceleration in development timelines, not overnight transformation.